Oxolife has established a collaboration with the Energy Balance, Puberty and Reproductive Health Group of the University of Cordoba (UCO), with the aim of evaluating the potential of the drug OXO-001. At the same time, to carry out this line of research, a collaboration has been established with the Maimonides Institute for Biomedical Research (Imibic), a pioneering center in the study and development of models with polycystic ovarian syndrome worldwide.
The drug, which has successfully tested its biosafety, could be one of the solutions to infertility problems in general and for women with polycystic ovary in particular.
MORE INFORMATION: La biotecnológica Oxolife y la UCO ensayan un nuevo fármaco para mejorar la fertilidad de las mujeres con ovario poliquístico